Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Institutional Ownership: 3.33% (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
96 GF Score
Price ¥38.30
GF Value ¥38.83
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co Institutional Ownership?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 -1.29% 96 Institutional Ownership is 3.33% as of Aug. 18, 2026. GuruFocus rates SHSE:600211 with a GF Score™ of 96/100 and a GF Value™ of ¥38.83 (Fairly Valued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tibet Rhodiola Pharmaceutical Holding Co's institutional ownership is 3.33%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tibet Rhodiola Pharmaceutical Holding Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tibet Rhodiola Pharmaceutical Holding Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Tibet Rhodiola Pharmaceutical Holding Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co Institutional Ownership Chart

Tibet Rhodiola Pharmaceutical Holding Co Historical Data

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 3.14 3.14 3.33 3.33 3.33 3.34 3.34 3.35 3.33 3.33
SHSE:600211
96GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.33% mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Institutional Ownership of 3.33% as of Aug. 18, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors.
Is Tibet Rhodiola Pharmaceutical Holding Co's Institutional Ownership too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Institutional Ownership is 3.33%. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Institutional Ownership compare to ZTS?
Tibet Rhodiola Pharmaceutical Holding Co's Institutional Ownership of 3.33% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. Tibet Rhodiola Pharmaceutical Holding Co's current Institutional Ownership is 3.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥38.83, compared to a current price of ¥38.30 — trading 1.4% below its estimated fair value. The current Institutional Ownership is 3.33%. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Institutional Ownership is 3.33% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥38.30 is trading 1.4% below its estimated GF Value™ of ¥38.83. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • Institutional Ownership: 3.33%
  • GF Value™: ¥38.83 vs. price of ¥38.30 (1.4% below fair value)
  • GF Score™: 96/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
96GF Score

Get the complete analysis for SHSE:600211

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.30
Price
¥38.83
GF Value